Intra-Cellular Therapies Inc. was given approval by the FDA to commercially launch Caplyta, a new drug to treat schizophrenia.Original Article
Novel Drug For Schizophrenia To Hit The Market Following FDA Approval
You may also like
Ninth Circuit Upholds FDA’s Authority to Regulate...
Skinny-Label Lives to See Another Day
Bring Out Your Meds! Bring Out Your Meds!
Homeopathic Industry Group Wants Court to Exclude It...
A Reversal on Sequencing? Proposed Legislation Would...
FDA Guidance Outlines a Framework for the Evaluation...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.